Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409326 | 0.85 | GRM5 (0.33) | GRM5MEN1TP53PKMKMT2A | |
| SCHEMBL1178757 | 0.85 | NPC1 (0.33) | TP53NPC1GAARAB9A | |
| SCHEMBL1178671 | 0.85 | GRM5 (0.35) | GRM5MEN1TP53PKMKMT2A | |
| SCHEMBL1179095 | 0.79 | S1PR1 (0.37) | NPC1RAB9A | |
| SCHEMBL1179884 | 0.76 | NPC1 (0.35) | MEN1TP53KMT2ANPC1GAA | |
| SCHEMBL1179249 | 0.75 | S1PR1 (0.34) | NPC1RAB9A | |
| SCHEMBL3409322 | 0.73 | GRM5 (0.33) | GRM5MEN1TP53PKMKMT2A | |
| SCHEMBL1180023 | 0.70 | KDM4E (0.53) | MEN1TP53KMT2ANPC1GAA | |
| SCHEMBL16481895 | 0.68 | L3MBTL1 (0.47) | GRM5GAA | |
| SCHEMBL1178943 | 0.67 | S1PR1 (0.35) | TP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | GRM5 1872/4885MEN1 4570/4885TP53 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.